BioCentury | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

...at Brahms AG, the company responsible for procalcitonin becoming the gold standard biomarker for sepsis. After Brahms...
BioCentury | Feb 1, 2016
Company News

Thermo Fisher, Samsung Electronics sales and marketing update

...Thermo Fisher launched the Samsung IB BRAHMS PCT assay in Europe to diagnose sepsis. The in...
BioCentury | May 23, 2013
Tools & Techniques

Revisiting adrenomedullin in preeclampsia

...women. The group plans to use an antibody-based assay for pro-adrenomedullin (pro-AM) marketed by the Brahms...
BioCentury | Oct 8, 2012
Company News

bioMerieux, Thermo Fisher deal

...bioMerieux and Thermo Fisher extended their non-exclusive 2004 deal to use Thermo Fisher's BRAHMS Procalcitonin (PCT...
...Waltham, Mass. bioMerieux and Thermo Fisher extended their non-exclusive 2004 deal to use Thermo Fisher's BRAHMS...
BioCentury | Feb 6, 2012
Company News

Thermo Fisher, Abbott sales and marketing update

Thermo Fisher will make its B.R.A.H.M.S. Procalcitonin (PCT) sepsis assay available on Abbott's ARCHITECT "I" and "ci" series of immunochemistry analyzers. Thermo Fisher will manufacture the assay and have exclusive distribution rights in the EU....
BioCentury | Jul 25, 2011
Company News

Alere, Thermo Fisher deal

Alere received worldwide rights to integrate Thermo Fisher's B.R.A.H.M.S. biomarkers on Alere's point-of-care Triage diagnostic tests. Triage is a rapid immunoassay that measures biomarkers in blood, plasma and urine. Biomarkers to be integrated include Procalcitonin...
BioCentury | Jun 27, 2011
Clinical News

BRAHMS copeptin assay regulatory update

...The U.K.'s NICE issued final guidance on Thermo Fisher's BRAHMS copeptin assay in combination with cardiac...
...The agency said additional trials of the assay are needed to support adoption of the BRAHMS...
...appraisal (see BioCentury, March 21). Thermo Fisher gained the test through its 2009 acquisition of Brahms AG...
BioCentury | Mar 21, 2011
Clinical News

BRAHMS Copeptin blood test regulatory update

...The U.K.'s NICE issued an appraisal consultation document recommending against use of Thermo Fisher's BRAHMS copeptin...
...The agency said additional trials of the assay are needed to support adoption of the BRAHMS...
...meeting scheduled for April 20. Thermo Fisher gained the test through its 2009 acquisition of Brahms AG...
BioCentury | Nov 2, 2009
Company News

Thermo Fisher sales and marketing update

...acute myocardial infarction (AMI), is undisclosed. Thermo Fisher acquired the test through its acquisition of Brahms AG...
BioCentury | Oct 5, 2009
Company News

Brahms, Thermo Fisher deal

...announced acquisition of Brahms for €330 million ($482 million) in cash (see BioCentury, Sept. 14). Brahms AG...
Items per page:
1 - 10 of 16
BioCentury | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

...at Brahms AG, the company responsible for procalcitonin becoming the gold standard biomarker for sepsis. After Brahms...
BioCentury | Feb 1, 2016
Company News

Thermo Fisher, Samsung Electronics sales and marketing update

...Thermo Fisher launched the Samsung IB BRAHMS PCT assay in Europe to diagnose sepsis. The in...
BioCentury | May 23, 2013
Tools & Techniques

Revisiting adrenomedullin in preeclampsia

...women. The group plans to use an antibody-based assay for pro-adrenomedullin (pro-AM) marketed by the Brahms...
BioCentury | Oct 8, 2012
Company News

bioMerieux, Thermo Fisher deal

...bioMerieux and Thermo Fisher extended their non-exclusive 2004 deal to use Thermo Fisher's BRAHMS Procalcitonin (PCT...
...Waltham, Mass. bioMerieux and Thermo Fisher extended their non-exclusive 2004 deal to use Thermo Fisher's BRAHMS...
BioCentury | Feb 6, 2012
Company News

Thermo Fisher, Abbott sales and marketing update

Thermo Fisher will make its B.R.A.H.M.S. Procalcitonin (PCT) sepsis assay available on Abbott's ARCHITECT "I" and "ci" series of immunochemistry analyzers. Thermo Fisher will manufacture the assay and have exclusive distribution rights in the EU....
BioCentury | Jul 25, 2011
Company News

Alere, Thermo Fisher deal

Alere received worldwide rights to integrate Thermo Fisher's B.R.A.H.M.S. biomarkers on Alere's point-of-care Triage diagnostic tests. Triage is a rapid immunoassay that measures biomarkers in blood, plasma and urine. Biomarkers to be integrated include Procalcitonin...
BioCentury | Jun 27, 2011
Clinical News

BRAHMS copeptin assay regulatory update

...The U.K.'s NICE issued final guidance on Thermo Fisher's BRAHMS copeptin assay in combination with cardiac...
...The agency said additional trials of the assay are needed to support adoption of the BRAHMS...
...appraisal (see BioCentury, March 21). Thermo Fisher gained the test through its 2009 acquisition of Brahms AG...
BioCentury | Mar 21, 2011
Clinical News

BRAHMS Copeptin blood test regulatory update

...The U.K.'s NICE issued an appraisal consultation document recommending against use of Thermo Fisher's BRAHMS copeptin...
...The agency said additional trials of the assay are needed to support adoption of the BRAHMS...
...meeting scheduled for April 20. Thermo Fisher gained the test through its 2009 acquisition of Brahms AG...
BioCentury | Nov 2, 2009
Company News

Thermo Fisher sales and marketing update

...acute myocardial infarction (AMI), is undisclosed. Thermo Fisher acquired the test through its acquisition of Brahms AG...
BioCentury | Oct 5, 2009
Company News

Brahms, Thermo Fisher deal

...announced acquisition of Brahms for €330 million ($482 million) in cash (see BioCentury, Sept. 14). Brahms AG...
Items per page:
1 - 10 of 16